Compare Bank of Nova Scotia (BNS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Regeneron Pharmaceuticals Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $107.95B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Bank of Nova Scotia is the larger of the two by market cap, and Bank of Nova Scotia pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| BNS | REGN | |
|---|---|---|
Market Cap | $107.95B | $83.19B |
Sector | Financials | Health |
52-Week High | $90.29 | $812.27 |
52-Week Low | $56.41 | $555.51 |
Dividend Yield | 3.65% | 0.47% |
Enterprise Value | — | $77.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.85, up 0.6% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong analyst support, a 52.63% buy rating, and a solid dividend yield. Revenue grew to $37.10B in 2025, though net income margin dipped slightly to 20.99%.
Outlook is positive with earnings growth and strategic acquisitions like MapleMark Bank driving upside. Risks include economic sensitivity and competitive pressures. Wall Street sentiment leans bullish, but investors should monitor credit conditions and interest rate impacts on banking performance.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
